PENK

PENK. Proenkephalin (PENK) is a precursor protein that is enzymatically cleaved to produce several active opioid peptides, including Met-enkephalin and Leu-enkephalin. These endogenous opioids function as crucial neurotransmitters and neuromodulators in the central nervous system and peripheral nervous system, playing key roles in modulating pain perception, stress response, and reward pathways. The gene encoding proenkephalin is highly conserved across vertebrates and is expressed in diverse tissues, with significant implications for both basic neurobiology and clinical medicine.

Gene and protein structure

The *PENK* gene is located on chromosome 8 in humans and consists of multiple exons that are transcribed and processed into messenger RNA. This mRNA is translated into the preproenkephalin protein, which contains a characteristic signal peptide for entry into the secretory pathway. The full-length proprotein includes several copies of the enkephalin sequences flanked by pairs of basic amino acid residues, which serve as recognition sites for proteolytic cleavage by specific prohormone convertase enzymes such as PC1/3 and PC2. The gene's promoter region contains regulatory elements responsive to various transcription factors, allowing its expression to be modulated by signals including cyclic AMP and glucocorticoids.

Function and mechanism

Upon processing, proenkephalin yields the pentapeptides Met-enkephalin (Tyr-Gly-Gly-Phe-Met) and Leu-enkephalin (Tyr-Gly-Gly-Phe-Leu), which are the primary active products. These endogenous opioids exert their effects primarily by binding to and activating G protein-coupled receptors, notably the delta opioid receptor (DOR) and the mu opioid receptor (MOR). This activation inhibits adenylate cyclase activity, reduces calcium channel conductance, and potentiates potassium channel efflux, leading to neuronal hyperpolarization and decreased neurotransmitter release. Enkephalins are involved in analgesia within circuits such as the periaqueductal gray and spinal cord, contribute to the regulation of mood and affect via the limbic system, and influence motor control in regions like the basal ganglia.

Clinical significance

Dysregulation of the proenkephalin system has been implicated in several neurological disorders and psychiatric conditions. Reduced levels of enkephalins or altered *PENK* expression have been associated with heightened pain sensitivity in conditions like fibromyalgia and some neuropathic pain states. In Parkinson's disease, changes in enkephalin expression in the striatum are part of the pathological basal ganglia circuitry. Furthermore, abnormalities in the endogenous opioid system, including proenkephalin-derived peptides, are studied in the context of major depressive disorder, schizophrenia, and substance use disorder, particularly related to opioid and alcohol dependence. Measurement of the stable proenkephalin fragment penKid has emerged as a novel biomarker for assessing acute kidney injury in critical care settings.

Evolution and homologs

The *PENK* gene is part of the larger opioid precursor gene family, which also includes proopiomelanocortin (POMC) and prodynorphin (PDYN). These genes likely arose from a common ancestral gene through gene duplication events early in vertebrate evolution. Proenkephalin and its peptide products are found in all major classes of vertebrata, from fish to mammals, indicating a conserved evolutionary role in stress and nociceptive systems. Homologs of enkephalins have been identified in diverse species, including amphibians and birds, though the number of peptide repeats within the precursor can vary. The high degree of sequence conservation, particularly in the enkephalin core motif, underscores its fundamental biological importance.

Research and applications

Current research on proenkephalin spans from molecular neuroscience to therapeutic development. Studies utilize knockout mouse models lacking the *PENK* gene to investigate its role in pain behavior, emotionality, and addiction. In pharmacology, enkephalin analogs and inhibitors of their degrading enzymes, such as enkephalinase inhibitors, are being explored as potential analgesics with potentially lower addiction liability than classical morphine-like opioids. Gene therapy approaches aiming to deliver the *PENK* gene to specific brain regions have been investigated in animal models for chronic pain. Additionally, the role of proenkephalin-derived peptides in immune modulation and cardiovascular function remains an active area of investigation in systems biology. Category:Genes Category:Neuropeptides Category:Opioids